1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

22 Mar 2024
Admin
News Article

23andMe Begins Phase 1 Trial for 23ME-01473 Antibody

23andMe Launches Phase 1 Trial for 23ME-01473 Antibody Targeting ULBP6

Overview

23andMe Holding Co. (Nasdaq: ME) has announced the initiation of a Phase 1 clinical trial for 23ME-01473 ('1473), targeting advanced solid tumors. This trial marks a significant milestone as the first participant receives dosing. The investigational antibody, ULBP6, targeted by '1473, was discovered through 23andMe's proprietary research platform, which utilizes the world's largest database of de-identified human genetic and phenotypic information. Remarkably, this marks the third drug target validated by 23andMe's research platform to enter clinical trials in less than four years.

Words from 23andMe

Jennifer Low, Head of Therapeutics Development at 23andMe, expressed enthusiasm, stating, “Entering the clinic with this exciting new dual-mechanism NK-cell activator reinforces the ability of the 23andMe Therapeutics team, and the potential of our research platform, to discover and develop new therapies informed by human genetics.”

Projected Mechanism of '1473

'1473 targets ULBP6 to enhance anti-tumor immunity via NK and T cells. ULBPs, found on cancer cells, bind to NKG2D receptors on NK and T cells.
Cancer cells evade immune recognition by shedding ULBP ligands, acting as immunosuppressive decoys.
'1473 aims to block this binding, potentially restoring immune cell recognition and killing of cancers.
Additionally, '1473 is Fc-effector enhanced, offering another mechanism for NK cells to induce cancer cell death.

The identification of ULBP6 as a potential drug target was facilitated by 23andMe's immuno-oncology (I/O) genetic signature, utilizing genetic data to identify immune-related genes impacting cancer biology and risk.

Phase 1 Study

The Phase 1 '1473 study is a first-in-human, multi-center, open-label trial assessing safety and tolerability in individuals with locally advanced or metastatic solid malignancies progressing after standard therapy.
This study will also evaluate '1473's pharmacokinetic and pharmacodynamic profile to establish the optimal dose and schedule for further clinical investigations.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!